CMS Decision on Whether to Keep Part B Drug Payment Cuts for 340B Hospitals Could Come as Soon as Today

CMS could disclose as soon as today whether it will continue, end, or modify its nearly 30% cut in certain hospitals’ Medicare Part B reimbursement for 340B-purchased drugs.

The U.S. Centers for Medicare & Medicaid Services (CMS) could disclose as soon as today whether it will continue, end, or modify the nearly 30% cut in certain hospitals’ Medicare Part B reimbursement for 340B-purchased drugs.

Read More »

Grassley Asks HHS General Counsel Nominee About Drug Companies “Harming Access” to 340B

HHS General Counsel nominee Sam Bagenstos answered questions about the 340B program during his Oct. 26 Senate Finance confirmation hearing.

A GOP U.S. Senator who has been active on 340B matters for decades last week asked President Biden’s pick to be the U.S. Health and Human Services Department’s top lawyer if HHS could be doing more to protect the 340B

Read More »

Biden Administration Wants to Scuttle Azar’s Rule to Automatically Snuff Out HHS Regulations

The Biden administration says it wants to withdraw or repeal ex-HHS Secretary Alex Azar’s final rule that will automatically extinguish all HHS regulations if HHS does not renew each regulation within a certain timeframe. | C-SPAN

The Biden administration last Friday, as widely expected, proposed withdrawing or repealing a Trump administration final rule that will automatically extinguish all U.S. Health and Human Services (HHS) regulations if HHS does not renew each regulation within a certain timeframe.

Read More »

Breaking: Federal Judge Vacates HRSA’s May 17 Letter to Lilly on 340B Contract Pharmacies, Sends Matter Back to Agency

A federal district judge late this afternoon struck down, as arbitrary and capricious, HRSA's finding that Lilly's 340B contract pharmacy policies violate the 340B statute. However, the judge said that manufacturers should not be allowed to unilaterally impose conditions on the location and delivery of 340B drugs and sent the matter back to HRSA.

A federal district judge in Indianapolis late this afternoon set aside and vacated the federal government’s May 17 finding that drug manufacturer Eli Lilly’s denials of 340B ceiling prices when covered entities use contract pharmacies violates the 340B statute.

Read More »

Both Sides in AstraZeneca’s 340B Contract Pharmacy Case Want a Quick Ruling, but It’s Unclear if They Will Get One

Both sides in AstraZeneca's 340B contract pharmacy lawsuit want an expedited decision, but for very different reasons.

Drug manufacturer Astra Zeneca and the federal government both want a federal district judge in Delaware to rule quickly in the drug company’s lawsuit over the government’s 340B contract pharmacy requirements.

Please Login or Become a

Read More »

Federal Court Decision on Novel Arkansas 340B Contract Pharmacy Law Might Not Come Until 2023

A federal district judge in Little Rock might not rule on Arkansas’s 340B nondiscrimination law might until sometime in 2023.

A federal court ruling on the legality and constitutionality of Arkansas’s 340B nondiscrimination law might not come until sometime in 2023.

Please Login or Become a Paid Subscriber to View this Content

Read More »

HRSA Orders Two Drug Makers to Repay 340B Entities After Audits Show Overcharges

HRSA has ordered Akorn Inc. and BioComp Pharma to repay 340B covered entities for overcharges following audits.

The U.S. Health Resources Services Administration (HRSA) has ordered two drug manufacturers that it audited—Akorn Inc. and BioComp Pharma—to repay 340B covered entities for overcharges.

Please Login or Become a Paid Subscriber to View this Content

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
×